of isatin-quinazoline (6a-f and 7a-e)/phthalazine (8a-f)/quinoxaline (9a-f) hybrids. The antiproliferative activity of the target hybrids was assessed towards HT-29 (colon), ZR-75 (breast) and A-549 (lung) human cancer cell lines. Hybrids 8b-d emerged as the most active antiproliferative congener in this study. Compound 8c induced apoptosis via increasing caspase 3/7 activity by about 5-fold in the
在继续致力于开发有效的基于Isatin的抗癌剂方面,我们采用了分子杂交方法来设计和合成四套不同的Isatin-
喹唑啉(6a-f和7a-e)/
酞嗪(8a) -f)/
喹喔啉(9a-f)杂种。评估了目标杂种对HT-29(结肠),ZR-75(乳腺癌)和A-549(肺)人癌
细胞系的抗增殖活性。杂种8b-d成为本研究中最活跃的抗增殖同源物。化合物8c通过在A-549人癌
细胞系中使胱天
蛋白酶3/7活性增加约5倍来诱导凋亡。另外,在细胞周期效应测定中,它表现出G1期增加而S和G2 / M期减少。此外,其抑制浓度的50%值为9。对多重耐药的NCI-H69AR肺癌细胞株为5 µM。杂合体8c还通过与大鼠肝微粒体一起孵育进行了体外代谢研究,并借助
液相色谱-质谱法分析了所得代谢产物。